According to International Agency for Research on Cancer, the number of new cancer cases per year is expected to rise to 23.6 million by 2030 globally. In recent times, cell line development and its applications are considered as potential tools in oncology research. Cell lines are projected to be used for development of new treatment pathway for various disease including cancer and neurological diseases.
According to a latest research by Future Market Insights (FMI), the global cell line development market size is anticipated to account for over US$ 7,200 Mn, in terms of value, by 2028 end. The report on cell line development market further projects significant growth potential with CAGR at 7.2% through 2028.
Rapid increase in prevalence of cancer and neurology disorders and lack of efficient treatment solution for these diseases has created the need of more advanced and efficient treatment pathway. Companies and government organizations are investing on research and development activities and are also focusing more on cell line development in search of new cellular pathway to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide boost to cell line development market.
In recent time the contract research organizations are focusing on cell line development and cell line research activities. According to National Institutes of Health (NIH) the estimated total federal spending on all type of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, government is supporting cell line development through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST).
Regenerative medicines are the next generation treatment solution and Cell Line Development or Cell Culture is a vital part for regenerative medicine. Increasing demand of regenerative medicines in cancer treatment would positively impacting the growth of Cell Line Development market over the forecast period.
The biopharmaceutical companies operating in development of novel drug line are expected to hold promising revenue opportunity in cell line development market.
Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-7566
Sales Analysis of Cell line Development from 2013 to 2021 Vs Market Outlook for 2022 to 2028
The market value for cell line development holds nearly 11.7% of the overall US$ 37.3 Mn drug discovery market in 2021.
Compared to the existing mammalian expression systems, the human cell lines possess the ability to produce proteins analogous to naturally synthesized proteins in the human body. This property is advantageous for the advancement in protein therapeutics, and acts as a heavy driver towards the growth of the biopharmaceutical industry. The growth of these industries pulls up the demand of cell line development market. The advantage of using human cell lines for protein production is factored in through the prospects of the resultant recombinant protein to bear post-translational modifications which are consistent with the endogenous human proteins.
Increasing burden of disease had propelled the development of new treatment pathways for diseases such as cancer and neurological disorders. The applications of hybridoma cell lines and recombinant cell lines in the development of therapeutic proteins has led to the growth in demand of cell line development market. The human cell lines, specifically the stem cell lines hold a potential stance for the treatment of various degenerative diseases, and hence paves way to novel drug therapy in regenerative medicine.
Moreover, the increasing development and production of biosimilars, owing to the patent expiry of branded therapeutics has positively impacted the growth of the cell line development market. The global scale development of bio therapeutics with cell line development has further fostered the development of a number of protein based therapeutics, assisting the growth of high-expression cell lines. These factors promote the expansion of the cell line development market on a global scale.
The global cell line development market expanded at 6.1% CAGR over the past 8 years from 2013 to 2021. The market is expected to expand at a considerable growth rate over the next six years (2022-2028) at a CAGR of close to 7.5%
Future Market Insights (FMI) has segmented the cell line development market based on product type, cell line source type, end user, type of cell line and region.
Product type segment in cell line development market is segmented into media and reagents, equipment and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. Reagent and media segment in cell line development market is expected witness noteworthy growth in terms of revenue owing to rapid increase in demand in cell culture and cell based assays.
Cell line development market by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipate to witness significant growth in overall cell line development market. This growth of mammalian cells segment in cell line development market is driven by increased production of biologics drugs which require mammalian cells. Increasing antibody production is the major driving factor behind the growth of mammalian cell lines segment in cell line development market.
Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection. For example, Gaucher’s disease, which is a genetic disorder characterized by lack of β-glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produces in mammalian cell lines. Mammalian cell lines are also useful in production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease causing agents in the body. For example Under cell line type segment in cell line development market, recombinant cell line development are the most demanding type of cell line due to large application in biologics production, protein interaction, gene activation, toxicity testing and drug screening.
Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period
North America and Europe cell line development market will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to increased number of research organization engaged in novel biologics and biosimilar fastest revenue growth in overall cell line development market.
The Asia Pacific region in Cell line development market is anticipate to witness increasing demand of biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.
FMI’s report tracks some of the key companies operating in the cell line development market, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.
Key Market Segments Covered in Cell line development Market Research
By Product Type:
- Reagent and Media
- Accessories and consumables
By Source Type:
- Mammalian cell line
- Non-mammalian cell line
By End User:
- Biopharmaceutical Companies
- Contract Research Organizations
- Academics and Research Institutes
- Biotechnology Companies
By Cell Lines:
- Recombinant cell lines
- Continuous cell lines
- Primary cell lines
- North America
- Latin America
- CIS & Russia